Our previous studies have indicated that the extracellular matrix protein, vitronectin, directs the localization of both plasminogen activator inhibitor, type I, (PAI-1), and urokinase-type plasminogen activator (uPA) to vitronectin dependent focal adhesion sites on human fibroblasts and sarcoma (HT-1080) cells. The hypothesis to be tested in this proposal is that matrix bound vitronectin will promote plasminogen- dependent cell mediated focal proteolysis of the matrix and subsequent directed cell migration through the matrix. Vitronectin conformers will be compared for their ability to mediate cell adhesion and PAI-1 binding. To determine whether collagen is the binding site for vitronectin in the matrix, the effect of collagenase digestion of fibroblast monolayers on the binding of vitronectin to and the release of vitronectin from the matrix will be tested. The collagen/matrix binding site in vitronectin will be identified by limited protein digestion and deletional analysis of vitronectin cDNA expressed by COS-1 cells. The integrin receptor for vitronectin on HT-1080 cells which triggers uPA receptor clustering will be identified by immunoprecipitation and immunolocalization using vitronectin receptor (alphavbeta3 and alphavbeta5) antibodies. The possible physical linkage of the uPA receptor and the vitronectin receptor of HT-1080 cells will be examined by chemical crosslinking and receptor immunoprecipitations using anti-vitronectin receptor and anti- uPA receptor antibodies. to address the role of vitronectin in focal proteolysis and directed cell migration, a series of mutant vitronectin cDNAs, [normal (wild type) vitronectin (VNwt), vitronectin which cannot bind collagen (VN-coll), vitronectin which cannot bind PAI-1, (VN-PAI-1), or vitronectin which cannot mediate cell adhesion (VN-RGD)] will be constructed by oligo-nucleotide-directed mutagenesis. Vitronectin cDNAs will be transfected into COS-1 cells by DEAE dextran precipitation. All expressed vitronectin proteins will be assessed for the ability to bind collagen and PAI-1, support cell adhesion and direct the clustering of urokinase receptors on HT-1080 cell surfaces. cDNAs directing the synthesis of vitronectins deficient in only one of these activities will be used to transfect HT-1080 cells. Plasminogen dependent proteolysis of each cell line will be measured by plating cells onto radiolabeled matrix molecules and quantifying the release of radioactivity. To determine whether the various vitronectins can localize proteolytic activity to focal areas, cell lines will be plated onto rhodamine conjugated matrix molecules which have been covalently coupled to glass coverslips. If necessary, the conformer of vitronectin required for cell binding will be induced by the addition of thrombin/anti-thrombin III complexes to the assay. Directed migration of transfected cell lines will be assessed using modified Boyden chambers with filters precoated with matrigel or Type I collagen gels. this project will define the potentially important role for vitronectin in the regulation of cell surface proteolysis and will investigate the consequences of this regulation for directed cell migration. These studies will contribute towards the understanding of processes such as angiogenesis and tumor invasion.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA058626-03
Application #
2099304
Study Section
Pathobiochemistry Study Section (PBC)
Project Start
1993-07-15
Project End
1998-04-30
Budget Start
1995-05-01
Budget End
1996-04-30
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Albany Medical College
Department
Physiology
Type
Schools of Medicine
DUNS #
City
Albany
State
NY
Country
United States
Zip Code
12208
Cho, Christina; Horzempa, Carol; Jones, David et al. (2016) The fibronectin III-1 domain activates a PI3-Kinase/Akt signaling pathway leading to ?v?5 integrin activation and TRAIL resistance in human lung cancer cells. BMC Cancer 16:574
Vial, Daniel; McKeown-Longo, Paula J (2016) Role of EGFR expression levels in the regulation of integrin function by EGF. Mol Carcinog 55:1118-23
Cho, Christina; Kelsh-Lasher, Rhiannon; Ambesi, Anthony et al. (2015) Cryptic activity within the Type III1 domain of fibronectin regulates tissue inflammation and angiogenesis. Curr Top Pept Protein Res 16:37-47
Kelsh, Rhiannon M; McKeown-Longo, Paula J; Clark, Richard A F (2015) EDA Fibronectin in Keloids Create a Vicious Cycle of Fibrotic Tumor Formation. J Invest Dermatol 135:1714-1718
Ambesi, Anthony; McKeown-Longo, Paula J (2014) Conformational remodeling of the fibronectin matrix selectively regulates VEGF signaling. J Cell Sci 127:3805-16
Kelsh, Rhiannon; You, Ran; Horzempa, Carol et al. (2014) Regulation of the innate immune response by fibronectin: synergism between the III-1 and EDA domains. PLoS One 9:e102974
Kelsh, Rhiannon M; McKeown-Longo, Paula J (2013) Topographical changes in extracellular matrix: Activation of TLR4 signaling and solid tumor progression. Trends Cancer Res 9:1-13
Vial, Daniel; McKeown-Longo, Paula J (2012) Epidermal growth factor (EGF) regulates ?5?1 integrin activation state in human cancer cell lines through the p90RSK-dependent phosphorylation of filamin A. J Biol Chem 287:40371-80
Ambesi, Anthony; McKeown-Longo, Paula J (2009) Anastellin, the angiostatic fibronectin peptide, is a selective inhibitor of lysophospholipid signaling. Mol Cancer Res 7:255-65
You, Ran; Klein, R Matthew; Zheng, Mingzhe et al. (2009) Regulation of p38 MAP kinase by anastellin is independent of anastellin's effect on matrix fibronectin. Matrix Biol 28:101-9

Showing the most recent 10 out of 20 publications